COMMUNIQUÉS West-GlobeNewswire

GlycoReset Supplement Facts Released: Consumer Safety Report Details New Analysis About Glyco Reset Ingredients & Side Effects Risk
22/07/2026
Berberine, Ceylon Cinnamon, Gymnema Sylvestre, Chromium Picolinate and Four More Compounds in the Glyco Reset Drops Formula Wilmington, DE, July 21, 2026 (GLOBE NEWSWIRE) -- These statements have not been evaluated by [...]
Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026; Annual General Meeting Planned for End of September 2026
22/07/2026
Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026; Annual General Meeting Planned for End of September 2026 Halle (Saale) / Munich, Germany, July 22 , 2026 - Vivoryon [...]
Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen's Rare Disease pipeline
22/07/2026
PARIS, FRANCE, 22 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK polyomavirus [...]
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
22/07/2026
WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular [...]
Ipsen finalise l'acquisition de Memo Therapeutics AG, ajoutant un actif premier de sa classe au portefeuille de maladies rares d'Ipsen
22/07/2026
PARIS, FRANCE, 22 JUILLET 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) a annoncé aujourd'hui avoir finalisé l'acquisition de Memo Therapeutics AG - une société de biotechnologie en phase avancée de développement - portant [...]
Picard Medical Announces Reverse Stock Split Following Stockholder Approval to Support Continued NYSE American Listing Compliance
22/07/2026
-Reverse stock split to support continued compliance with NYSE American continued listing standards- TUCSON, Ariz., July 21, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the "Company" or "Picard [...]
Jushi Holdings Inc. to Report Second Quarter 2026 Financial Results on July 28, 2026
21/07/2026
BOCA RATON, Fla., July 21, 2026 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH ) (OTCQX: JUSHF ) , a vertically integrated, multi-state cannabis operator, announced that it expects to [...]
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
21/07/2026
Peer-reviewed publication of ProstACT SELECT 1 results confirm the utility of 68 Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach 2 . Consistent with previously [...]
Coalition to Improve Access to Cancer Care Applauds Reintroduction of the Cancer Drug Parity Act
22/07/2026
WASHINGTON, July 21, 2026 (GLOBE NEWSWIRE) -- The Coalition to Improve Access to Cancer Care (CIACC), convened by the International Myeloma Foundation (IMF), applauds Senators Tina Smith (D-MN) and Jerry Moran (R-KS) [...]
OraSure Receives Emergency Use Authorization for Second Generation Ebola Test
21/07/2026
The rapid test detects the Bundibugyo virus associated with the current outbreak and can support the diagnosis of both symptomatic individuals and deceased patients. BETHLEHEM, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- [...]
Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC
22/07/2026
SHANGHAI, July 21, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
21/07/2026
WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular [...]
OrthoPediatrics Corp. to Report Second Quarter Financial Results on August 4, 2026
21/07/2026
WARSAW, Ind., July 21, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
Mobia Medical to Report Second Quarter 2026 Financial Results on August 11, 2026
21/07/2026
AUSTIN, Texas, July 21, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today [...]
Flyte Partners with Blade to Expand Vision Jet Distribution
21/07/2026
Flyte's Vision Jet Fleet to Be Featured on Blade Platform, Expanding Distribution across One of the Industry's Leading Air Mobility Networks Strategic Partnership Expected to Increase Aircraft Utilization, Customer [...]
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
21/07/2026
Study did not meet key efficacy objectives Favorable safety profile consistent with prior studies, including with new 450mg loading dose and up to 300mgQ4W regimen Profound systemic mast cell depletion, as evidenced by [...]
Dentsply Sirona to Host Second Quarter Conference Call on August 6th
21/07/2026
CHARLOTTE, N.C., July 21, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and live webcast on [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
21/07/2026
CONSHOHOCKEN, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition
21/07/2026
- Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has constrained other MEK [...]

Pages